作为这项研究的支持者， 辉瑞 深耕JAK通路30年，自1993年首次发现JAK激酶在皮肤免疫中的关键作用，研发团队历经数代化合物迭代，终于在2022年推出高选择性JAK1抑制剂阿布昔替尼，为临床提供了突破创新的治疗选择。

类风湿关节炎是我国致残率最高的慢性疾病之一，患者总数超500万人。临床数据显示，约30%的RA患者对现有主流生物制剂（如TNF抑制剂）存在应答不足或不耐受问题。恒瑞医药此次获批的艾玛昔替尼为高选择性JAK1抑制剂，通过精准阻断JAK1信号通路抑制炎症 ...

Incyte has entered into two large licensing deals for their JAK1/JAK2 inhibitors INCB28050 and INCB18424. In late December 2009, the worldwide rights to INCB28050, which is in mid-stage trials for ...

Ltd. has identified deuterated non-receptor tyrosine-protein kinase TYK2 and tyrosine-protein kinase JAK1, JAK2 and JAK3 inhibitors reported to be useful for the treatment of allergy, asthma, cancer, ...

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

The FDA has kicked off a priority review of Opzelura (ruxolitinib), a JAK1/JAK2 inhibitor it approved to treat atopic dermatitis in September, and aims to decide on the vitiligo indication by 18 ...